How big is Immunome, Inc.?

As of Jun 18, Immunome, Inc. has a market capitalization of 778.76 million, with net sales of 10.94 million and a net profit of -205.11 million over the latest four quarters. Shareholder's funds are 181.16 million, and total assets are 240.24 million.

As of Jun 18, Immunome, Inc. has a market capitalization of 778.76 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of Net Sales for the latest four quarters is 10.94 million, while the sum of Net Profit for the same period is -205.11 million.<BR><BR>As of Dec 24, the reporting period shows Shareholder's Funds at 181.16 million and Total Assets at 240.24 million.

What does Immunome, Inc. do?

Immunome, Inc. is a biopharmaceutical company focused on developing antibody therapeutics in oncology. As of March 2025, it reported net sales of $3 million and a net loss of $42 million, with a market cap of $778.76 million.

Overview: <BR>Immunome, Inc. is a biopharmaceutical company focused on discovering and developing antibody therapeutics, primarily in the oncology sector, and operates within the Pharmaceuticals & Biotechnology industry.<BR><BR>Financial Snapshot: <BR>Net Sales: 3 Million (Quarterly Results - Mar 2025) <BR>Net Profit: -42 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 778.76 Million (Micro Cap) <BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.03 <BR>Return on Equity: -55.69% <BR>Price to Book: 2.54 <BR><BR>Contact Details: <BR>Address: 665 STOCKTON DRIVE, SUITE 300, EXTON PA : 19341 <BR>Tel: 1 610 3213700 <BR>Fax: 1 302 6555049 <BR>Website: http://immunome.com/

Should I buy, sell or hold Immunome, Inc.?

Who are in the management team of Immunome, Inc.?

As of March 2022, the management team of Immunome, Inc. includes Mr. Michael Rapp (Chairman), Dr. Purnanand Sarma (President and CEO), Mr. Michael Morin (Chief Scientific Officer), and Mr. Richard Baron (Director).

As of March 2022, the management team of Immunome, Inc. includes the following individuals:<BR><BR>- Mr. Michael Rapp, who serves as the Chairman of the Board.<BR>- Dr. Purnanand Sarma, who is the President, Chief Executive Officer, and a Director.<BR>- Mr. Michael Morin, who holds the position of Chief Scientific Officer and is also a Director.<BR>- Mr. Richard Baron, who is a Director.

Is Immunome, Inc. overvalued or undervalued?

As of May 5, 2023, Immunome, Inc. is rated as risky due to overvaluation indicated by a negative P/E ratio, a -55.69% ROE, and high valuation metrics compared to peers, despite a 93.9% stock return over three years, which underperformed the S&P 500's 70.41% return.

As of 5 May 2023, the valuation grade for Immunome, Inc. has moved from does not qualify to risky, indicating a deterioration in its investment appeal. The company appears to be overvalued based on its financial metrics, particularly given its negative P/E ratio and ROE of -55.69%. Key ratios include a Price to Book Value of 2.59 and an EV to Sales ratio of 43.62, which suggest that the stock is priced significantly higher than its underlying assets and sales performance would justify.<BR><BR>In comparison to its peers, Immunome's valuation metrics are concerning; for instance, it has a P/E ratio of -4.5888 while its EV to EBITDA stands at -2.9278. This highlights a stark contrast with the industry expectations and raises questions about its future profitability. Additionally, while Immunome's stock returned 93.9% over the past three years, it underperformed against the S&P 500, which returned 70.41% in the same period, further reinforcing the notion that the stock may be overvalued.

Is Immunome, Inc. technically bullish or bearish?

As of October 3, 2025, Immunome, Inc. shows a bullish technical trend with strong momentum indicators, outperforming the S&P 500 significantly over the past week, month, and year-to-date.

As of 3 October 2025, the technical trend for Immunome, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, and both the weekly and monthly Bollinger Bands indicate a bullish stance. Daily moving averages also support a bullish outlook. However, the monthly KST is bearish, and the Dow Theory shows a mildly bullish position on both weekly and monthly time frames. <BR><BR>Immunome has outperformed the S&P 500 significantly over the past week (27.07% vs. 1.09%) and month (36.98% vs. 4.15%), while the year-to-date return of 35.69% also surpasses the S&P 500's 14.18%. Overall, the current technical stance is bullish with strong momentum indicators.